27/07/2026 Argenx to acquire Forte Biosciences and adding FB102 to its Immunology pipeline InnoCare's fadeucravacitinib met it primary endpoint in Phase 3 Psoriasis study Jacobio dosed the first patient in China in Phase 2a trial of JAB-8263 for Rheumatoid arthritis Bambusa Therapeutics reported preliminary Proof-of-concept data for BTT001 in Atopic Dermatitis Argenx to acquire Forte Biosciences and adding FB102 to its Immunology pipeline (Ref) Argenx announced that the compa

24/07/2026 Sanofi announced its decision not to submit amlitelimab in atopic dermatitis for global regulatory reviews Sanofi announced its decision not to submit amlitelimab in atopic dermatitis for global regulatory reviews (Ref) Sanofi announced the discontinuation of clinical development of amlitelimab (OX40-ligand) in moderate-to-severe atopic dermatitis (AD). The decision followed a strategic pipeline review, that concluded the overall efficacy and safety data did not su

21/07/2026 Nektar Therapeutics initiated the Phase 3 ZENITH AD Program evaluating rezpegaldesleukin in moderate-to-severe atopic dermatitis Nektar Therapeutics initiated the Phase 3 ZENITH AD Program evaluating rezpegaldesleukin in moderate-to-severe atopic dermatitis (Ref) Nektar Therapeutics announced the initiation of the two global registrational Phase 3, ZENITH AD-1 and ZENITH AD-2 trials evaluating rezpegaldesleukin (IL-2 receptor agonist) in patients who were ≥12 year

20/07/2026 AbelZeta received EMA PRIME designation for C-CAR168 in LN and SLE LAPIX Therapeutics completed patient enrollment in the RA arm of the ongoing LPX-TI641 clinical trial Almirall announced EMA acceptance of the pediatric filing for Ebglyss® in atopic dermatitis AbelZeta received EMA PRIME designation for C-CAR168 in LN and SLE (Ref) AbelZeta Pharma announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) had granted

09/07/2026 LEO Pharma announced Phase 2 results of tralokinumab in children with moderate-to-severe atopic dermatitis Fate Therapeutics received FDA clearance of its IND Application for FT839 in autoimmune LEO Pharma announced Phase 2 results of tralokinumab in children with moderate-to-severe atopic dermatitis (Ref) LEO Pharma announced positive results from the Phase 2, TRAPEDS-1 trial evaluated tralokinumab (Anti-IL-13) in children aged 6 to 11 years with moderate-to-sever

07/07/2026 Vera Therapeutics announced US FDA accelerated approval of TRUTAKNA™ for adults with primary IgA nephropathy Turn Therapeutics announced the final stage 2 design and data-driven expansion of the GX-03 phase 2 trial in Atopic Dermatitis Everest Medicines announced the closing of its exclusive licencing agreement with Travere Therapeutics for civorebrutinib Vera Therapeutics announced US FDA accelerated approval of TRUTAKNA™ for adults with primary IgA nephropathy (R

25/06/2026 Kymera Therapeutics completed enrollment in the Phase 2b trial of KT-621 in Atopic Dermatitis Tiziana announced that the last patient was dosed in its Phase 2 trial for the treatment of na-SPMS Leads Biolabs announced that its partner Oblenio Bio had closed a $62 million oversubscribed Series B financing to advance LBL-051 for autoimmune diseases into clinical development Kymera Therapeutics completed enrollment in the Phase 2b trial of KT-621 in Atopic Dermatitis

09/06/2026 US FDA approved a new every-eight week maintaince dosing option for Lilly’s lebrikizumab in moderate-to-severe atopic dermatitis US FDA accepted Takeda's application for Intravenous vedolizumab in Pediatric UC and CD US FDA approved a new every-eight week maintaince dosing option for Lilly’s lebrikizumab in moderate-to-severe atopic dermatitis (Ref) Eli lilly announced that the US FDA approved a regimen of one maintenance dose every eight weeks of a single injectio

07/05/2026 Incyte announced long-term data from Phase 3 study of ruxolitinib cream in adult patients with AD Incyte announced long-term data from Phase 3 study of ruxolitinib cream in adult patients with AD (Ref) Incyte announced final 24-week data from its Phase 3, TRuE-AD4 study which evaluated the efficacy and safety of Opzelura® (ruxolitinib) cream in adults with moderate atopic dermatitis (AD) who had an inadequate response, intolerance or contraindication to topical cor

28/03/2026 Biogen announced Phase 2 results for litifilimab for CLE Results from Sanofi’s Phase 3 studies in AD were presented AAD Alumis announced Phase 3 data for envudeucitinib for plaque psoriasis Incyte announced Phase 3 data for povorcitinib for HS Biogen announced Phase 2 results for litifilimab for CLE ( Ref ) Biogen announced positive results from part A of its Phase2/3 AMETHYST/ NCT05531565 study, which evaluated litifilimab (BDCA2) for the treatment of patients w

16/03/2026 Spyre Therapeutics announced results from the Phase 2 rheumatoid arthritis sub-study InnoCare Pharma announced that ICP-538 had been approved for clinical trials in China and had completed dosing of the first subject Lilly announced Phase 3 results of lebrikizumab in pediatric patients with moderate-to-severe AD Sun Pharma announced US FDA had accepted for review the sBLA for tildrakizumab for the treatment of adults with active PsA Spyre Therapeutics announced res

09/03/2026 Pfizer announced Phase 2 results of tilrekimig in AD Vertex announced Phase 3 results of Povetacicept in IgA Nephropathy Pfizer announced Phase 2 results of tilrekimig in AD ( Ref ) Pfizer announced positive topline results from its Phase 2 study that evaluated tilrekimig (PF-07275315; trispecific antibody targets Il-4, IL-13 and TSLP) for the treatment of adult patients with moderate to severe atopic dermatitis (AD) The study met its primary endpoint, demonstratin

02/03/2026 Lynk Pharmaceuticals announced positive Phase 3 data for zemprocitinib in moderate-to-severe atopic dermatitis Abbive announced topline results form a Phase 3 study that evaluated resankizumab subcutaneous induction in patients with CD Roche announced positive results from a Phase 3 study that evaluated fenebrutinib in patients with RMS Sanofi's rilzabrutinib earned orphan drug designation in Japan for IgG4-related disease Lynk Pharmaceuticals announced positive Ph

10/02/2026 US FDA accepted NDA and granted priority review for Takeda’s oveporexton as a potential first-in-class therapy for Narcolepsy Type 1 Evommune reported positive top-line data from Phase 2a POC trial of EVO301 in moderate-to-severe atopic dermatitis Kincell Bio partnered with Regcell to advance Treg cell therapies into clinical trials for autoimmune diseases US FDA accepted NDA and granted priority review for Takeda’s oveporexton as a potential first-in-class therapy